Whitehawk Therapeutics Schedules Three September Investor Conferences
Morristown-based oncology firm Whitehawk Therapeutics will engage with the financial community through a series of presentations this September. The Nasdaq-listed company aims to highlight its clinical-stage pipeline, including its proprietary antibody drug conjugate programs, at three major healthcare-focused investor events held throughout the month.
Management is set to hold private investor meetings at the Cantor Global Healthcare Conference on September 9 and the Wells Fargo 21st Annual Healthcare Conference on September 10. The schedule concludes on September 15 at the Morgan Stanley 24th Annual Global Healthcare Conference, where Chief Financial Officer Scott Giacobello and Chief Scientific Officer David Dornan, PhD, will participate in a scheduled fireside chat at 1:05 PM ET.
Whitehawk currently focuses on advancing its ADC portfolio, which includes candidates HWK-007, HWK-016, and HWK-206. These assets, in-licensed from WuXi Biologics, utilize the company’s proprietary Carbon Bridge Cysteine Re-pairing platform to enhance stability. Interested parties can access a live webcast of the Morgan Stanley presentation via the company’s investor relations website, with a replay available for 30 days.
Comments (0)
No comments yet. Be the first!